相似文献
1
Validation of LOH profiles for assessing oral cancer risk.
Cancer Prev Res (Phila). 2012 Sep;5(9):1075-7. doi: 10.1158/1940-6207.CAPR-12-0294. Epub 2012 Aug 21.
2
Genetic driver events in premalignancy: LOH validated for marking the risk of oral cancer.
Cancer Prev Res (Phila). 2012 Sep;5(9):1073-4. doi: 10.1158/1940-6207.CAPR-12-0220. Epub 2012 Aug 21.
3
Loss of heterozygosity (LOH) profiles--validated risk predictors for progression to oral cancer.
Cancer Prev Res (Phila). 2012 Sep;5(9):1081-9. doi: 10.1158/1940-6207.CAPR-12-0173. Epub 2012 Aug 21.
4
Predicting progression of oral dysplasia--letter.
Cancer Prev Res (Phila). 2013 Jun;6(6):614-5. doi: 10.1158/1940-6207.CAPR-13-0072. Epub 2013 Apr 16.
5
Predicting progression of oral dysplasia--response.
Cancer Prev Res (Phila). 2013 Jun;6(6):616. doi: 10.1158/1940-6207.CAPR-13-0111. Epub 2013 Apr 16.
6
Loss of heterozygosity and immunoexpression of PTEN in oral epithelial dysplasia and squamous cell carcinoma.
Exp Mol Pathol. 2020 Feb;112:104341. doi: 10.1016/j.yexmp.2019.104341. Epub 2019 Nov 13.
7
Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia.
Clin Cancer Res. 2000 Feb;6(2):357-62.
8
[Loss of heterozygosity as a tool in the evaluation of cancer risk in premalignant lesions of the head and neck].
Bull Cancer. 2000 Jun;87(6):446.
9
Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada.
Oncologist. 2016 Sep;21(9):1099-106. doi: 10.1634/theoncologist.2015-0433. Epub 2016 Jul 11.
10
Loss of p53 gene as a biomarker of high risk oral leukoplakias.
Indian J Biochem Biophys. 1997 Jun;34(3):266-73.
引用本文的文献
1
Loss of heterozygosity as a marker to predict progression of oral epithelial dysplasia to oral squamous cell carcinoma.
J Oral Maxillofac Pathol. 2018 May-Aug;22(2):155-160. doi: 10.4103/jomfp.JOMFP_151_18.
2
Characterization of epithelial oral dysplasia in non-smokers: First steps towards precision medicine.
Oral Oncol. 2018 Mar;78:119-125. doi: 10.1016/j.oraloncology.2018.01.028. Epub 2018 Feb 20.
3
Effect of human papillomavirus seropositivity and E2F2 promoter variants on risk of squamous cell carcinomas of oropharynx and oral cavity.
Carcinogenesis. 2016 Nov 1;37(11):1070-1078. doi: 10.1093/carcin/bgw095.
本文引用的文献
1
Cancer statistics, 2012.
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.
2
Reduced lung-cancer mortality with low-dose computed tomographic screening.
N Engl J Med. 2011 Aug 4;365(5):395-409. doi: 10.1056/NEJMoa1102873. Epub 2011 Jun 29.
3
Gene expression profiling predicts the development of oral cancer.
Cancer Prev Res (Phila). 2011 Feb;4(2):218-29. doi: 10.1158/1940-6207.CAPR-10-0155.
4
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer.
Cancer Prev Res (Phila). 2010 Jul;3(7):800-9. doi: 10.1158/1940-6207.CAPR-09-0163. Epub 2010 Jun 22.
5
Human papillomavirus and survival of patients with oropharyngeal cancer.
N Engl J Med. 2010 Jul 1;363(1):24-35. doi: 10.1056/NEJMoa0912217. Epub 2010 Jun 7.
6
Treatment and follow-up of oral dysplasia - a systematic review and meta-analysis.
Head Neck. 2009 Dec;31(12):1600-9. doi: 10.1002/hed.21131.
7
Outcome of oral dysplasia: a retrospective hospital-based study of 207 patients with a long follow-up.
J Oral Pathol Med. 2009 Jul;38(6):540-4. doi: 10.1111/j.1600-0714.2009.00782.x. Epub 2009 May 18.
8
Multiple aberrations of chromosome 3p detected in oral premalignant lesions.
Cancer Prev Res (Phila). 2008 Nov;1(6):424-9. doi: 10.1158/1940-6207.CAPR-08-0123.
9
Impact of second primary tumors on survival in head and neck cancer: an analysis of 2,063 cases.
Laryngoscope. 2008 Aug;118(8):1350-6. doi: 10.1097/MLG.0b013e318172ef9a.
10
Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers.
J Natl Cancer Inst. 2008 Mar 19;100(6):407-20. doi: 10.1093/jnci/djn025. Epub 2008 Mar 11.
Zotero 插件